Currently, Meyskens is continuing the clinical development of the Bowman-Birk inhibitor, a soybean-derived serine protease inhibitor, being tested as a human cancer-preventive agent.
Meyskens received a Bachelor of Science degree from the University of San Francisco, and his Medical Degree from University of California, San Francisco Medical School. He completed his postdoctoral education at the Laboratory of Tumor Cell Biology, National Cancer Institute and the Medicine Branch, National Institutes of Health.
Meyskens has received numerous honors and awards for his scientific accomplishments, including the American Society of Preventive Oncology Distinguished Achievement Award and the University of California Irvine Lauds & Laurels Faculty Achievement Award. Meyskens has published more than 100 peer-reviewed laboratory and clinical manuscripts on the topic of cancer prevention and control.
An active member of the AACR since 1979, Meyskens has served in various capacities, including as editorial board member of Cancer Prevention Research, chairperson of the Biology and Genetics of Early Detection special conference, and as a member of several committees.
Meyskens will give an award lecture entitled, Optimizing Chemoprevention by Minimizing Risk-Benefit and Maximizing Risk-Reduction, on Monday, November 17, 2008, at 5:00 p.m., during the Seventh Annual International Conference on Frontiers in Cancer Prevention Research. This foremost meeting on cancer prevention research will be held November 16 - 19, 2008, at the Gaylord National Resort, Washington, DC.
|Contact: Megan J. Davies|
American Association for Cancer Research